Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diffusion tensor MRI in Alzheimer's disease: Prediction and visualization of treatment effects of galantamine (Reminyl)
2005-003762-41Phase 4Active
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Sep 2006
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of galantamine in Alzheimer's disease (AD), sponsored by Ludwig Maximilian University of Munich. Primary endpoints: Hippocampus volume, Entorhinal cortex volume and 1 more. Started Sep 2006; status: active.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2005-003762-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003762-41.